Pancreatic Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Pancreatic Cancer Therapeutics & Diagnostics Market is segmented by Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments) and Diagnostics (Imaging, Biopsy, Endoscopic Ultrasound, and Other Diagnostics)) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

Pancreatic Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Pancreatic Cancer Therapeutics & Diagnostics Industry Overview

The Pancreatic Cancer Therapeutics and Diagnostics market is highly competitive, with many key players dominating the market. The presence of major market players like Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Myriad Genetics Inc., and Viatris Inc. is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations, to sustain the increasing market rivalry. For instance, in January 2021, Myriad Genetics Inc. entered into a strategic partnership with Illumina Inc. for the latter to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets, which can be used to detect pancreatic cancer.

Pancreatic Cancer Therapeutics & Diagnostics Market Leaders

  1. Myriad Genetics, Inc.

  2. Pfizer, Inc

  3. Novartis AG

  4. Bristol-Myers Squibb Company

  5. AstraZeneca plc

  6. *Disclaimer: Major Players sorted in no particular order
Pancreatic Cancer Therapeutics and Diagnostics Market Concentration

Pancreatic Cancer Therapeutics & Diagnostics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?